Stay updated on Pembrolizumab and TKI in CML MRD Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and TKI in CML MRD Clinical Trial page.

Latest updates to the Pembrolizumab and TKI in CML MRD Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedLocations section added and lists study sites by state (Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Idaho, Illinois, Iowa, Kansas, Kentucky, Maryland, Michigan, Minnesota, Missouri, Montana, Nebraska, New Jersey, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Virginia, Washington, West Virginia, Wisconsin, Wyoming) with Revision: v3.3.3. Per-state location subsections were removed, the HHS Vulnerability Disclosure link was removed, and the revision updated from v3.3.2.SummaryDifference1.0%

- Check20 days agoNo Change Detected
- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedThe page shows a new Revision: v3.3.2 added and a Revision: v3.3.1 removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check42 days agoChange DetectedRevision updated from v3.2.0 to v3.3.1.SummaryDifference0.0%

- Check50 days agoChange DetectedRecent update dates (2025-11-11 and 2025-11-13) appear on the study page, and an older funding notice was removed. These are maintenance updates that do not alter study content or results; to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check64 days agoChange DetectedUpdates to the study record history show new Last Update posts dated 2025-10-29 and 2025-10-28, with removals of September entries. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check93 days agoChange DetectedUpgrade to v3.2.0 with a new government-operating status notice and funding caveat; removes v3.1.0. This introduces current-operational caveats and directs users to status pages.SummaryDifference1%

Stay in the know with updates to Pembrolizumab and TKI in CML MRD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and TKI in CML MRD Clinical Trial page.